Cargando…

Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial

BACKGROUND: Ospemifene is a non-estrogen, tissue selective estrogen receptor agonist/antagonist, or selective estrogen receptor modulator, recently approved for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Postmenopausal dyspareunia is often associat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Constantine, G., Graham, S., Portman, D. J., Rosen, R. C., Kingsberg, S. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389697/ https://www.ncbi.nlm.nih.gov/pubmed/25252699 http://dx.doi.org/10.3109/13697137.2014.954996

Ejemplares similares

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy
por: Goldstein, S. R., et al.
Publicado: (2014)

Ospemifene for vulvar and vaginal atrophy: an overview
por: Palacios, Santiago
Publicado: (2020)

The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy
por: Nappi, R. E., et al.
Publicado: (2015)

Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy
por: Bruyniks, N., et al.
Publicado: (2016)

Effect of Ospemifene on Densitometric and Plasma Bone Metabolism Biomarkers in Postmenopausal Women Reporting Vulvar and Vaginal Atrophy (VVA)
por: Maffei, Silvia, et al.
Publicado: (2022)

Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies
por: López, Ana Rosa Jurado, et al.
Publicado: (2020)

Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
por: Palacios, Santiago, et al.
Publicado: (2016)

Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies
por: Blanco, Zuramis Estrada, et al.
Publicado: (2020)

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
por: Soe, Lin H, et al.
Publicado: (2013)

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
por: Wurz, Gregory T, et al.
Publicado: (2014)

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles
por: del Carmen Pingarrón Santofimia, María, et al.
Publicado: (2020)

Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use
por: Cagnacci, Angelo, et al.
Publicado: (2020)

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies
por: Lilue, Mariella, et al.
Publicado: (2020)

Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases
por: Goldstein, Andrew T., et al.
Publicado: (2016)

Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices
por: Goldstein, Irwin, et al.
Publicado: (2019)

Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials
por: Simon, James A., et al.
Publicado: (2018)

Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial
por: Archer, David F., et al.
Publicado: (2019)

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history
por: Kingsberg, Sheryl A., et al.
Publicado: (2019)

Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy
por: Shin, Jae Jun, et al.
Publicado: (2017)

Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial
por: Clayton, Anita H, et al.
Publicado: (2016)

The effect of vitamin D on vaginal atrophy in postmenopausal women
por: Rad, Parastou, et al.
Publicado: (2015)

Management of Vaginal Atrophy: Implications from the REVIVE Survey
por: Wysocki, Susan, et al.
Publicado: (2014)

Effect of Trigonella foenum (fenugreek) vaginal cream on vaginal atrophy in postmenopausal women
por: Mazalzadeh, Fakhriyeh, et al.
Publicado: (2020)

Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy
por: Kingsberg, SA, et al.
Publicado: (2010)

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program
por: Constantine, Ginger D., et al.
Publicado: (2015)

Efficacy of Hormonal and Nonhormonal Approaches to Vaginal Atrophy and Sexual Dysfunctions in Postmenopausal Women: A Systematic Review
por: Sarmento, Ayane Cristine Alves, et al.
Publicado: (2022)

Vaginal dehydroepiandrosterone compared to other methods of treating vaginal and vulvar atrophy associated with menopause
por: Pięta, Wojciech, et al.
Publicado: (2021)

Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies
por: Salcedo, Félix Lugo, et al.
Publicado: (2020)

Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study
por: Rodríguez, Silvia Pilar González
Publicado: (2020)

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence
por: Archer, David F., et al.
Publicado: (2015)

Multidisciplinary Overview of Vaginal Atrophy and Associated Genitourinary Symptoms in Postmenopausal Women
por: Goldstein, Irwin, et al.
Publicado: (2013)

A Review of Pharmacological Treatments for Vaginal Atrophy in Postmenopausal Women in Iran
por: Rashidi Fakari, Farzaneh, et al.
Publicado: (2020)

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
por: Zohrabi, Ilnaz, et al.
Publicado: (2020)

Current treatment options for postmenopausal vaginal atrophy
por: Naumova, Iuliia, et al.
Publicado: (2018)

Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy
por: Parish, Sharon J, et al.
Publicado: (2013)

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy
por: Constantine, Ginger D., et al.
Publicado: (2017)

Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey
por: Nappi, R. E., et al.
Publicado: (2016)

Comparison of the Efficacy of Vaginal Hyaluronic Acid to Estrogen for the Treatment of Vaginal Atrophy in Postmenopausal Women: A Systematic Review
por: Albalawi, Nada Saleh, et al.
Publicado: (2023)

Sexual function and distress in postmenopausal women with chronic insomnia: exploring the role of stress dysregulation
por: Kalmbach, David A, et al.
Publicado: (2019)

Attitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study
por: Utian, W. H., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j74l768nmm2guo0ino6tfruvpf